$NEUP

Neuphoria Therapeutics Inc.

Neuphoria Therapeutics is a clinical-stage biotechnology company focused on therapies for central nervous system disorders. Its lead candidate, BNC210, is an oral modulator of the alpha7 nicotinic acetylcholine receptor that was studied for social anxiety disorder and post-traumatic stress disorder. The social anxiety program is discontinued, and no BNC210 clinical trial is active; the PTSD program is clinic-ready. Neuphoria has limited internal research and development activity and maintains intellectual property and interests in partnered programs. Neuphoria earns potential milestone payments, royalties and other proceeds through collaborations and licenses. Merck controls and funds development of alpha7 receptor positive allosteric modulators, while Pfizer controls the KAT6 program licensed through the former CTx CRC. Carina Biotech controls development of the CNA3103 cell therapy program. Neuphoria is headquartered in Burlington, Massachusetts.

No enriched coverage for $NEUP in the last 7 days.

No SEC Form 4 filings for $NEUP in the last 30 days.

See all $NEUP insider activity →
Low

Neuphoria Therapeutics Inc. (NEUP): Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, the Board of Directors (the “Board”) of Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a Delaware corporation, entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Abivax (ABVX) is expected to report a first-half loss of $1.08 per share on revenue of $1.86M. Marygold (MGLD) and Neuphoria (NEUP) reported Q4 losses. Accenture (ACN) partnered with Anthropic, shares up 8.1%. Lobo (LOBO) reported H1 growth, shares up 26.7%.

Neuphoria Therapeutics Inc. (NEUP): Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029891401ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 23, 2026, BY AND AMONG SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, INC. AND NEUPHORIA THERAPEUTICS INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, IN

NEUP sentiment & insider activity

Recent NEUP coverage spans financial news, mergers & acquisitions and corporate actions.

What's driving NEUP

  • The amendment is a routine corporate governance filing with limited commercial impact.

    SEC EDGAR 8-K · Oct 23, 2026

  • Earnings miss creates slight negative sentiment.

    benzinga.com · Sep 21, 2026

  • The 8-K discloses NEUP’s entry into a merger agreement, which typically shifts valuation to deal terms and raises deal-completion and financing/timing risk.

    SEC EDGAR 8-K · Jul 23, 2026

  • The merger provides a defined exit/combination outcome and ties Neuphoria’s equity value to the combined company’s funding and clinical timeline.

    rttnews.com · Jul 23, 2026

  • Neuphoria shareholders face a takeout/dilution event with CVR-linked upside, making the stock sensitive to milestone definitions and closing conditions.

    investegate.co.uk · Jul 23, 2026

AlphAI scores every news story that mentions NEUP with an AI model for sentiment and relevance, and aggregates insider trades from Neuphoria Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NEUP

Score

Neuphoria Therapeutics Inc. (NEUP): Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, the Board of Directors (the “Board”) of Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a Delaware corporation, entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as

$NEUPMedM&A· target · $89M · definitive

Neuphoria Therapeutics Inc. (NEUP): Entry into a Material Definitive Agreement

Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029891401ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 23, 2026, BY AND AMONG SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, INC. AND NEUPHORIA THERAPEUTICS INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, IN

$NEUPMedAI 8/10

Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing

Scancell Holdings plc (SCLP.L) and Neuphoria Therapeutics Inc. (NEUP) agreed to an all-share merger, with Scancell shareholders owning 85.5% and Neuphoria shareholders 14.5%. The deal includes up to $89m financing via equity and debt, including BlackRock-managed debt. Proceeds will fund iSCIB1+ Phase 3 milestones, with a primary readout in H2 2028. Shareholder approval is pending.

Merger and Financing

Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) announced an all-share merger where Scancell will acquire Neuphoria. The combined company plans to list on Nasdaq under symbol SCLT. Scancell expects up to $89m financing via equity and debt, including $39.1m private placement, about $15m UK equity, and up to $25m debt. Shareholder approval is required.

Related tickers